CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


ACT-20-CMWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug59 ACT-20-MSC Wiki 1.00
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.06

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.06

There is one clinical trial.

Clinical Trials


1 A Phase 1/2 Randomized, Placebo-Controlled Trial of ACT-20 in Patients With Severe COVID-19 Pneumonia

The primary objective of this study is determine the safety and efficacy of ACT-20-MSC (allogenic human umbilical derived mesenchymal stem cells) and ACT-20-CM (allogenic human umbilical derived mesenchymal stem cells in conditioned media) in patients with moderate to severe COVID-19 pneumonia.

NCT04398303 COVID-19 Pneumonia Biological: ACT-20-MSC Biological: ACT-20-CM Biological: Placebo
MeSH:Pneumonia
HPO:Pneumonia

Primary Outcomes

Measure: Mortality at day 30

Time: 30 days post treatment

Secondary Outcomes

Description: Number of ventilator-free days

Measure: Ventilated Subjects - Ventilator Free Days

Time: 28 days post treatment

Description: Improvement in ventilator settings: Minute ventilation, PEEP, FiO2

Measure: Ventilated Subjects - Improvement in Ventilator Settings

Time: 28 days post treatment, or until off of ventilator

Description: Days of step-down O2 therapy as evidenced by: improvement in required volume, change to nasal cannula or face mask delivery or improvement in required concentration.

Measure: High-Flow O2 Support Subjects - Step-Down O2 Therapy

Time: 30 days post treatment, or until off of high-flow O2 support

Description: Respiration Rate < 30 for > 24 hours.

Measure: High Flow O2 Support Subjects - Respiration Rate

Time: 30 days post treatment, or until off of high-flow O2 support

Description: Number of ICU-free days

Measure: Both Ventilated and High-Flow O2 Support Subjects - ICU-Free Days

Time: 30 days post treatment, or until off of ventilator or high-flow O2 support

Description: Improvement in pulmonary function as evidenced by A-A oxygen gradient, O2 saturation

Measure: Both Ventilated and High-Flow O2 Support Subjects - Pulmonary Function Improvement

Time: 30 days post treatment, or until off of ventilator or high-flow O2 support

Description: Increased Berlin Criteria score > 24 hours

Measure: Both Ventilated and High-Flow O2 Support Subjects - Increased Berlin Score

Time: 30 days post treatment, or until off of ventilator or high-flow O2 support


Related HPO nodes (Using clinical trials)